Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: 24 of 31 brokerages rate Boston Scientific a buy, while five recommend holding and two recommend selling. The average 12-month price target is $71.62.
• Quarterly results exceeded expectations: Boston Scientific reported adjusted EPS of $0.86 versus the $0.83 consensus and revenue of $5.44 billion, up 7.5% year over year. The company guided for third-quarter EPS of $0.80–$0.82 and full-year EPS of $3.28–$3.32.
• Management and insiders signaled confidence: The board authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares, while insiders purchased approximately $9.9 million worth of stock over the past three months.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the thirty-one brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and twenty-four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $71.6154.

A number of research analysts have issued reports on the company. Evercore set a $65.00 price target on Boston Scientific in a research report on Monday, July 6th. Stifel Nicolaus set a $60.00 price objective on shares of Boston Scientific in a research note on Wednesday, July 29th. BTIG Research reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, July 29th. TD Cowen decreased their target price on shares of Boston Scientific from $61.00 to $56.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, Weiss Ratings cut shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Tuesday, July 7th.

Boston Scientific Price Performance

NYSE BSX opened at $50.42 on Tuesday. The company has a 50-day moving average price of $45.80 and a two-hundred day moving average price of $60.25. Boston Scientific has a 52 week low of $42.20 and a 52 week high of $109.50. The stock has a market cap of $73.07 billion, a price-to-earnings ratio of 20.41, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger acquired 2,250 shares of the firm's stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares of the company's stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the company's stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company's stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 204,322 shares of company stock valued at $9,939,221. Insiders own 0.34% of the company's stock.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Outfitters Financial LLC raised its holdings in shares of Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider's stock worth $2,291,000 after buying an additional 110 shares in the last quarter. Natural Investments LLC boosted its stake in Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider's stock valued at $384,000 after buying an additional 112 shares in the last quarter. Patton Fund Management Inc. boosted its stake in Boston Scientific by 5.5% in the 4th quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider's stock valued at $217,000 after buying an additional 118 shares in the last quarter. Bridgewater Advisors Inc. grew its position in Boston Scientific by 1.2% in the fourth quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider's stock valued at $921,000 after acquiring an additional 123 shares during the period. Finally, CYBER HORNET ETFs LLC raised its stake in Boston Scientific by 3.4% during the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider's stock worth $391,000 after acquiring an additional 132 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source